Lymphoma Tissue Bank Core

The tissue core facilitates research on lymphoid malignancies by members of City of Hope's Comprehensive Cancer Center and supports two tissue banks.
The tissue bank core provides services in the following areas:
  • Acquisition and banking of fresh and paraffin-fixed tissues of lymphoma patients at City of Hope, including specimens obtained prospectively and retrospectively obtaining specimens from patients previously biopsied elsewhere;
  • Comprehensive work-up of lymphoma specimens to ensure correct diagnosis and classification, including immunohistochemical, molecular pathologic, and cytogenetic studies.
  • Performance and assistance in routine histologic processing and immunohistochemical staining of lymphoma tissues, including paraffin embedding, sectioning and H&E staining of human tissue, animal tissue, and preparations from cell lines, as well as specialized histologic services such as preparation of multitumor blocks or tissue microarrays to the specifications of researchers
  • Performance and assistance in Laser Capture microdissections from paraffin or frozen sections to obtain enrichment of specific cell types including isolation of malignant cells for analysis of proteins, RNA and/or DNA content.
  • Consultation services to other SPORE investigators.
The Hematopoietic cell tissue bank collects bone marrow, peripheral blood and peripheral blood stem cell samples from lymphoma patients undergoing autologous peripheral stem cell transplant (aPBSCT). This core prospectively collects and stores fresh blood and marrow samples from patients undergoing aPBSCT for lymphoma. Samples are obtained pre-transplant and post-transplant at 100 days, 6 months, 1 year, and then annually through 5 years after transplant. In addition, aliquots of the PBSC autograft are also banked. The core also collects and enters follow up outcome information for all patients.
The core uses an IRB approved protocol for sample and data collection. The core also follows patients who have received their initial transplant treatment but who are not under current follow-up at City of Hope, by contacting the treating physician, and if necessary, recalling the patient to City of Hope for clinical evaluation, blood draw and bone marrow biospy. 
Core Leaders: John Chan, M.D., and Guido Marcucci, M.D.